GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Provexis PLC (LSE:PXS) » Definitions » Short-Term Debt

Provexis (LSE:PXS) Short-Term Debt : £0.00 Mil (As of Sep. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Provexis Short-Term Debt?

Provexis's Short-Term Debt for the quarter that ended in Sep. 2023 was £0.00 Mil.

Provexis Short-Term Debt Historical Data

The historical data trend for Provexis's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provexis Short-Term Debt Chart

Provexis Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Provexis Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Provexis Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Provexis Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Provexis's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Provexis (LSE:PXS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Provexis PLC (LSE:PXS) » Definitions » Short-Term Debt
Comparable Companies
LSE:STX LSE:CHLL AQSE:ANA LSE:HELD LSE:N4P AQSE:APOL LSE:VLG LSE:CEL ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX HKSE:03692 TSE:4507
Traded in Other Exchanges
PXS.GB:UK
Address
2 Blagrave Street, I Ford, Reading, Berkshire, GBR, RG1 1AZ
Website
https://www.provexis.com
Provexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is a patented, natural, breakthrough ingredient which helps with platelet aggregation. Fruitflow reduces the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can result in heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.